2nd Qtr & Interim Rslts-Pt3

AstraZeneca PLC 1 August 2000 PART 3 5 SEGMENT ANALYSIS 1st 1st 2nd 2nd 1st 1st Quarter Quarter Quarter Quarter Half Half 2000 1999 2000 1999 2000 1999 USDm USDm USDm USDm USDm USDm ------------------ ----- ----- ----- ----- ----- ----- Sales by class of business Healthcare 3,861 3,630 3,945 3,752 7,806 7,382 Other trading 31 21 26 28 57 49 ------------------ ----- ----- ----- ----- ----- ----- Ongoing Operations 3,892 3,651 3,971 3,780 7,863 7,431 Agrochemicals (to be discontinued) 706 663 975 949 1,681 1,612 Specialties (discontinued) - 296 - 319 - 615 ------------------ ----- ----- ----- ----- ----- ----- Group 4,598 4,610 4,946 5,048 9,544 9,658 ------------------ ----- ----- ----- ----- ----- ----- Operating profit/ (loss) before exceptional items Healthcare 985 880 1,073 954 2,058 1,834 Other trading (9) (3) (3) (11) (12) (14) ------------------ ----- ----- ----- ----- ----- ----- Ongoing Operations 976 877 1,070 943 2,046 1,820 Agrochemicals (to be discontinued) 101 71 242 212 343 283 Specialties (discontinued) - 31 - 40 - 71 ------------------ ----- ----- ----- ----- ----- ----- Group 1,077 979 1,312 1,195 2,389 2,174 ------------------ ----- ----- ----- ----- ----- ----- Operating profit/ (loss) before exceptional items as a percentage of sales % % % % % % ------------------ ----- ----- ----- ----- ----- ----- Healthcare 25.5 24.2 27.2 25.4 26.4 24.8 ------------------ ----- ----- ----- ----- ----- ----- Ongoing Operations 25.1 24.0 26.9 24.9 26.0 24.5 ------------------ ----- ----- ----- ----- ----- ----- 6 PRODUCTS AND TERRITORIAL SEGMENT SALES ANALYSIS % Growth --------------- 1st 1st Cons- Half Half tant 2000 1999 Act- Curr- Healthcare USDm USDm ual ency ------------------------------------ ----- ----- ----- ----- Gastrointestinal: Losec 2,967 2,848 4% 7% Others 22 24 (8%) - ------------------------------------ ----- ----- ----- ----- Total Gastrointestinal 2,989 2,872 4% 7% ------------------------------------ ----- ----- ----- ----- Cardiovascular: Zestril 661 602 10% 12% Tenormin 253 247 2% 3% Seloken 261 257 2% 5% Plendil 233 216 8% 11% Atacand 124 73 70% 78% Imdur 49 59 (17%) (14%) Others 203 216 (6%) (1%) ------------------------------------ ----- ----- ----- ----- Total Cardiovascular 1,784 1,670 7% 10% ------------------------------------ ----- ----- ----- ----- Respiratory: Pulmicort 353 370 (5%) 1% Accolate 114 74 54% 55% Rhinocort 114 99 15% 18% Bricanyl 66 73 (10%) (6%) Oxis 56 41 37% 47% Others 26 29 (10%) (3%) ------------------------------------ ----- ----- ----- ----- Total Respiratory 729 686 6% 11% ------------------------------------ ----- ----- ----- ----- Oncology: Zoladex 364 331 10% 11% Nolvadex 275 287 (4%) (5%) Casodex 220 166 33% 35% Arimidex 82 63 30% 36% Others 15 12 25% 33% ------------------------------------ ----- ----- ----- ----- Total Oncology 956 859 11% 12% ------------------------------------ ----- ----- ----- ----- Specialist/Hospital: Diprivan 284 327 (13%) (11%) Xylocaine 117 128 (9%) (11%) Marcaine 45 42 7% 9% Naropin 27 22 23% 28% Seroquel 204 95 115% 116% Zomig 132 86 53% 58% Merrem 78 77 1% 9% Other Products 313 345 (9%) (7%) Astra Tech 58 55 5% 12% Salick Health Care 90 118 (24%) (24%) ------------------------------------ ----- ----- ----- ----- Total Specialist/Hospital 1,348 1,295 4% 6% ------------------------------------ ----- ----- ----- ----- Total Healthcare 7,806 7,382 6% 8% ------------------------------------ ----- ----- ----- ----- 6 PRODUCTS AND TERRITORIAL SEGMENT SALES ANALYSIS (CONTINUED) % Growth --------------- 1st 1st Cons- Half Half tant 2000 1999 Act- Curr- Healthcare USDm USDm ual ency ------------------------------------ ----- ----- ----- ----- Territorial Analysis USA: Pharmaceuticals 3,920 3,470 13% 13% Salick Health Care 90 118 (24%) (24%) ------------------------------------ ----- ----- ----- ----- Japan 374 304 23% 8% France 450 423 6% 18% Germany 353 449 (21%) (13%) Italy 319 317 1% 12% Sweden 172 184 (7%) (3%) UK 338 392 (14%) (12%) Rest of World 1,790 1,725 4% 9% ------------------------------------ ----- ----- ----- ----- Total Healthcare 7,806 7,382 6% 8% ------------------------------------ ----- ----- ----- ----- Constant currency % growth has been calculated excluding the effects arising from exchange rate movements. % Growth --------------- 1st 1st Cons- Half Half tant 2000 1999 Act- Curr- Agrochemicals USDm USDm ual ency ------------------------------------ ----- ----- ----- ----- Product Analysis Herbicides: Non-Selective 468 369 27% 28% Selective 450 490 (8%) (5%) ------------------------------------ ----- ----- ----- ----- Total Herbicides 918 859 7% 9% Insecticides 270 230 17% 19% Fungicides 457 475 (4%) 2% Others 36 48 (25%) (19%) ------------------------------------ ----- ----- ----- ----- Total Agrochemicals 1,681 1,612 4% 8% ------------------------------------ ----- ----- ----- ----- Territorial Analysis North America 615 576 7% 7% Latin America 209 165 27% 27% Europe 600 633 (5%) 4% Asia, Africa, Australasia 257 238 8% 6% ------------------------------------ ----- ----- ----- ----- Total Agrochemicals 1,681 1,612 4% 8% ------------------------------------ ----- ----- ----- ----- Constant currency % growth has been calculated excluding the effects arising from exchange rate movements. 6 PRODUCTS AND TERRITORIAL SEGMENT SALES ANALYSIS (CONTINUED) 1st 1st 2nd 2nd Quarter Quarter % Growth Quarter Quarter % Growth 2000 1999 Constant 2000 1999 Constant Healthcare USDm USDm Currency USDm USDm Currency ------------------ ----- ----- ----- ----- ----- ----- Gastrointestinal: Losec 1,588 1,414 15% 1,379 1,434 (1%) Others 11 12 - 11 12 - ------------------ ----- ----- ----- ----- ----- ----- Total Gastrointestinal 1,599 1,426 15% 1,390 1,446 - ------------------ ----- ----- ----- ----- ----- ----- Cardiovascular: Zestril 276 301 (5%) 385 301 30% Tenormin 119 124 (2%) 134 123 8% Seloken 106 112 (1%) 155 145 10% Plendil 115 108 10% 118 108 12% Atacand 56 32 84% 68 41 73% Imdur 23 32 (25%) 26 27 - Others 99 106 (1%) 104 110 - ------------------ ----- ----- ----- ----- ----- ----- Total Cardiovascular 794 815 1% 990 855 18% ------------------ ----- ----- ----- ----- ----- ----- Respiratory: Pulmicort 174 190 (1%) 179 180 5% Accolate 55 28 100% 59 46 28% Rhinocort 41 43 - 73 56 32% Bricanyl 34 38 (6%) 32 35 (6%) Oxis 27 20 45% 29 21 48% Others 14 17 (12%) 12 12 8% ------------------ ----- ----- ----- ----- ----- ----- Total Respiratory 345 336 9% 384 350 15% ------------------ ----- ----- ----- ----- ----- ----- Oncology: Zoladex 167 165 3% 197 166 19% Nolvadex 139 143 (4%) 136 144 (8%) Casodex 115 91 29% 105 75 41% Arimidex 37 27 44% 45 36 31% Others 7 7 14% 8 5 60% ------------------ ----- ----- ----- ----- ----- ----- Total Oncology 465 433 9% 491 426 15% ------------------ ----- ----- ----- ----- ----- ----- Specialist/Hospital: Diprivan 164 149 13% 120 178 (31%) Xylocaine 54 61 (13%) 63 67 (7%) Marcaine 21 20 10% 24 22 9% Naropin 13 10 40% 14 12 17% Seroquel 82 47 74% 122 48 156% Zomig 65 39 72% 67 47 47% Merrem 36 38 - 42 39 18% Other Products 150 169 (9%) 163 176 (9%) Astra Tech 28 27 11% 30 28 14% Salick Health Care 45 60 (25%) 45 58 (22%) ------------------ ----- ----- ----- ----- ----- ----- Total Specialist /Hospital 658 620 8% 690 675 4% ------------------ ----- ----- ----- ----- ----- ----- Total Healthcare 3,861 3,630 9% 3,945 3,752 8% ------------------ ----- ----- ----- ----- ----- ----- 6 PRODUCTS AND TERRITORIAL SEGMENT SALES ANALYSIS (CONTINUED) 1st 1st 2nd 2nd Quarter Quarter % Growth Quarter Quarter % Growth 2000 1999 Constant 2000 1999 Constant Healthcare USDm USDm Currency USDm USDm Currency ------------------ ----- ----- ----- ----- ----- ----- Territorial Analysis USA: Pharmaceuticals 1,976 1,679 18% 1,944 1,791 9% Salick Health Care 45 60 (25%) 45 58 (22%) ------------------ ----- ----- ----- ----- ----- ----- Japan 156 127 8% 218 177 7% France 231 211 22% 219 212 13% Germany 175 249 (22%) 178 200 (2%) Italy 153 160 7% 166 157 17% Sweden 87 98 (6%) 85 86 2% UK 153 193 (19%) 185 199 (5%) Rest of World 885 853 10% 905 872 10% ------------------ ----- ----- ----- ----- ----- ----- Total Healthcare 3,861 3,630 9% 3,945 3,752 8% ------------------ ----- ----- ----- ----- ----- ----- Constant currency % growth has been calculated excluding the effects arising from exchange rate movements. 1st 1st 2nd 2nd Quarter Quarter % Growth Quarter Quarter % Growth 2000 1999 Constant 2000 1999 Constant Agrochemicals USDm USDm Currency USDm USDm Currency ------------------ ----- ----- ----- ----- ----- ----- Product Analysis Herbicides: Non-Selective 193 146 33% 275 223 24% Selective 160 193 (12%) 290 297 - ------------------ ----- ----- ----- ----- ----- ----- Total Herbicides 353 339 7% 565 520 11% Insecticides 109 100 13% 161 130 26% Fungicides 226 203 21% 231 272 (12%) Others 18 21 (9%) 18 27 (26%) ------------------ ----- ----- ----- ----- ----- ----- Total Agrochemicals 706 663 12% 975 949 5% ------------------ ----- ----- ----- ----- ----- ----- Territorial Analysis North America 186 171 9% 429 405 6% Latin America 75 63 19% 134 102 31% Europe 324 311 17% 276 322 (7%) Asia, Africa, Australasia 121 118 - 136 120 11% ------------------ ----- ----- ----- ----- ----- ----- Total Agrochemicals 706 663 12% 975 949 5% ------------------ ----- ----- ----- ----- ----- ----- Constant currency % growth has been calculated excluding the effects arising from exchange rate movements. Information for US Investors RECONCILIATION TO UNITED STATES ACCOUNTING PRINCIPLES The group profit and loss account and group balance sheet set out on pages 12, 13 and 14 are prepared in accordance with generally accepted accounting principles in the United Kingdom (UK GAAP) which differ in certain material respects from those generally accepted in the United States (US GAAP). The differences as they apply to AstraZeneca PLC are explained in the group's 1999 Annual Report and Form 20-F. The approximate effects on group income and shareholders' equity of the GAAP differences are shown below. 1st 1st Half Half 2000 1999 Income attributable to Shareholders USDm USDm ------------------------------------ ----- ----- Net income for the period under UK GAAP 1,548 832 Pre-acquisition results of Astra (413) ------------------------------------ ----- Previously presented Zeneca Group PLC income 419 Adjustments to conform to US GAAP Purchase accounting adjustments, (including goodwill and intangibles): - deemed acquisition of Astra - in-process research and development - (3,315) - inventory step-up - (826) - amortisation and other acquisition adjustments (878) (299) - others (14) (42) Divestment of Specialties business - 253 Capitalisation, less disposals and amortisation, of interest 21 - Capitalisation less amortisation of software costs 76 - Deferred taxation (13) 388 Pension expense (19) (64) Post-retirement benefits/plan amendment 2 2 Restructuring costs (25) - Unrealised gains on foreign exchange 5 2 ------------------------------------ ----- ----- Net income/(loss) in accordance with US GAAP 703 (3,482) ------------------------------------ ----- ----- Net income/(loss) per Ordinary Share under US GAAP (basic) USD0.40 USD(2.55) Net income/(loss) per Ordinary Share under US GAAP (diluted) USD0.40 USD(2.55) ------------------------------------ ----- ----- RECONCILIATION TO UNITED STATES ACCOUNTING PRINCIPLES (CONTINUED) 30 June 31 Dec 2000 1999 Shareholders' equity USDm USDm ------------------------------------ ----- ----- Shareholders' equity under UK GAAP 10,636 10,302 Adjustments to conform to US GAAP Purchase accounting adjustments, (including goodwill and intangibles): - deemed acquisition of Astra - goodwill 13,374 14,202 - tangible and intangible fixed assets 10,244 11,174 - others 481 490 Capitalisation, less disposals and amortisation, of interest 164 151 Deferred taxation - on fair value of Astra (2,904) (3,172) - others (388) (247) Dividend 406 834 Pension expense (191) (172) Post-retirement benefits/plan amendment (29) (31) Software costs capitalised 105 29 Restructuring costs 94 119 Others 88 56 ------------------------------------ ----- ----- Shareholders' equity in accordance with US GAAP 32,080 33,735 ------------------------------------ ----- ----- Shareholder Information ANNOUNCEMENTS AND MEETINGS --------------------------------------------------------------------------- Announcement of third quarter and nine months results 25 October 2000 Preliminary announcement of full year results and announcement of second interim dividend 8 February 2001 DIVIDENDS --------------------------------------------------------------------------- The Board has declared a first interim dividend of 0.23 dollars, 15.3 pence, SEK 2.10 per Ordinary Share in respect of the year 2000 using a conversion rate of US dollars to pounds sterling of 1 : 0.6647 and US dollars to Swedish Kronor of 1 : 9.1230. In 1999 AstraZeneca PLC declared a first interim dividend of 0.23 dollars, 14.2 pence, SEK 1.89 per Ordinary Share using a conversion rate of US dollars to pounds sterling of 1:0.6194 and US dollars to Swedish Kronor of 1:8.2044. Following the abolition of United Kingdom Advance Corporation Tax (ACT) with effect from 6 April 1999, private individuals or corporate shareholders owning less than 10% of the voting power of AstraZeneca resident in Sweden or the US will be entitled to a tax credit of one ninth of the dividend (10% of the gross dividend) although in practice the tax credit will be nullified by withholding tax. Each shareholder should consult their tax adviser for advice on the tax consequences of the dividend in their particular situation. The record date for the first interim dividend payable on 23 October 2000 (in the UK, Sweden and the US) is 8 September 2000. Ordinary Shares will trade ex-dividend on the London Stock Exchange from 4 September 2000 and on the Stockholm Stock Exchange from 6 September 2000. ADSs will trade ex-dividend on the New York Stock Exchange from 6 September 2000 TRADEMARKS -------------------------------------------------------------------------- All product or brand names included in Note 6 of this Interim Statement and the following names are trademarks of, or licensed to, AstraZeneca PLC or its subsidiary companies: Amistar Gramoxone Iressa Karate Nexium Prilosec Respules Rapimelt 'Rhinocort Aqua' Toprol XL Touchdown Viozan For simplicity, sales are reported under the above lead brand names, whereas some compounds are sold under several brand names to address separate market niches. ADDRESSES FOR CORRESPONDENCE -------------------------------------------------------------------------- Registrar and Depositary Registered Office Swedish Securities Transfer Office for ADRs Register Centre The AstraZeneca Morgan Guaranty 15 Stanhope Gate VPC AB Registrar Trust Company London Box 7822 Lloyds TSB of New York W1Y 6LN S-103 97 Stockholm Registrars ADR Service Sweden The Causeway Center Worthing PO Box 842006 West Sussex Boston BN99 6DA MA 02284-2006 Tel: (01903) Tel: (781) Tel: (020) Tel: (8) 502 541 575 4328 7304 5000 402 9000 CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS -------------------------------------------------------------------------- In order to utilise the 'Safe Harbor' provisions of the United States Private Securities Litigation Reform Act of 1995, AstraZeneca is providing the following cautionary statement. This Interim Report contains forward- looking statements with respect to the financial condition, results of operations and businesses of AstraZeneca. By their nature, forward-looking statements and forecasts involve risk and uncertainty because they relate to events and depend on circumstances that will occur in the future. There are a number of factors that could cause actual results and developments to differ materially from that expressed or implied by these forward-looking statements. These factors include, among other things, exchange rate fluctuations, the risk that research and development will not yield new products that achieve commercial success, the impact of competition, price controls and price reductions, the risk of loss or expiration of patents or trade marks, difficulties of obtaining and maintaining governmental approvals for products, the risk of substantial product liability claims, exposure to environmental liability and the risks related to the difficulty of integrating Astra's and Zeneca's large and complex businesses on a timely basis and realising synergies.

Companies

AstraZeneca (AZN)
UK 100
FTSE quotes by TradingView

Latest directors dealings

All directors dealings today